Astellas CEO Yasukawa On Enabling Faster R&D
TPDs One Beneficiary
Executive Summary
Keeping the company focus on launching innovating drugs, Astellas CEO Kenji Yasukawa talks in part one of this exclusive interview on how the Japanese firm transformed its R&D processes to allow more flexible and agile decision-making beyond the wall of multiple sections.
You may also be interested in...
R&D Reorg Helps Astellas Move Swiftly With Protein Degraders
In selecting targeted protein degradation as a new Primary Focus area within its R&D effort, Astellas has moved rapidly to develop a potential first-in-class KRAS G12D degrader candidate ASP3082, helped by a reorganization last year to develop a more agile research function. The Japanese firm sees very broad potential for TPDs beyond oncology in the longer term.
As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics
As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.